secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-08-11T11:32:26+00:00
Accession:  0001404644-26-000056
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene Q2 net loss $34.5M; NGN-401 100% milestone gains; cash to 1Q29
------------------------------------------------------------------------

- Q2 2026 net loss $34.5M vs $22.0M YoY; R&D $25.5M, G&A $11.2M.
- Cash $225.4M at June 30; pro forma $360.2M after $134.8M net from July offering; runway into 1Q29.
- NGN-401 Phase 1/2: 100% (N=10) improved CGI-I and gained ≥1 milestone; avg 4.7 milestones, no plateau through 30 months.
- Embolden topline data expected 2H 2027; PPQ runs for BLA complete by end-2026; NGN-401 well-tolerated (N=35).
- Oversubscribed public offering raised ~$144M gross proceeds, including full underwriter option exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/0001404644-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000056/ngne-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer